Stock listing

NASDAQ:TECX Tectonic Therapeutic, Inc. Stock

Home listing (NASDAQ) of Tectonic Therapeutic, Inc.

Follow Tectonic Therapeutic, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TECX

$20.73 USD -0.31 (-1.5%)

Close on Nov 20, 2026

Past year +14.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$20.41 – $21.57 USDNov 20, 2026
Volume
268,829 sharesNov 20, 2026
Market cap
$413.5M USDAt the close on Nov 20, 2026 · price × 19.95M shares outstanding
52-week range
$16.77 – $39.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.34M USDMedian day 188,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tectonic Therapeutic, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TECX · Home$20.73 USD-0.31 (-1.5%)268,829$20.70$21.57$20.41$21.04Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TECX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$20.73-0.31-1.5%$20.70$21.57$20.41268,829
$21.04+0.96+4.8%$20.08$21.31$20.08169,433
$20.08-0.90-4.3%$20.91$21.10$19.76144,206
$20.98-0.16-0.8%$21.07$21.42$20.53237,429
$21.14+0.10+0.5%$20.96$21.29$20.11300,637
$21.04-0.92-4.2%$21.75$21.75$20.20121,952
$21.96-0.010.0%$22.19$22.49$21.73134,015
$21.97+0.08+0.4%$21.82$22.80$21.14192,783
$21.89+1.25+6.1%$21.18$22.09$20.34129,559
$20.64+1.22+6.3%$19.00$20.89$18.92308,034
$19.42-0.88-4.3%$20.30$20.30$19.01109,567
$20.30+1.32+7.0%$19.57$20.57$19.33221,504
$18.980.000.0%$19.13$19.74$18.76198,953
$18.98-0.80-4.0%$19.78$19.94$18.54183,870
$19.78-0.72-3.5%$20.51$20.51$19.56146,257
$20.50-0.06-0.3%$20.92$21.44$20.36139,590
$20.56+0.22+1.1%$20.12$20.77$19.99215,885
$20.34+0.39+2.0%$20.09$20.54$19.74226,968
$19.95-0.12-0.6%$20.00$20.52$19.75151,222
$20.07-1.02-4.8%$21.03$22.31$19.83145,000
$21.09-0.75-3.4%$21.86$22.28$20.97251,400
$21.84+0.010.0%$21.86$22.30$21.53152,800
$21.83+0.68+3.2%$21.22$22.44$20.99144,500
$21.15+0.50+2.4%$20.78$21.30$20.45203,000
$20.65-0.65-3.1%$21.35$21.51$20.55175,400
$21.30+0.34+1.6%$21.08$21.51$21.06187,400
$20.96-0.35-1.6%$21.22$21.75$20.60190,800
$21.31-1.04-4.7%$22.23$22.38$21.02164,000
$22.35-0.98-4.2%$22.99$23.12$22.26103,900
$23.33+0.58+2.5%$22.74$23.61$22.74110,700
$22.75+0.04+0.2%$22.56$22.96$21.59167,700
$22.71+0.30+1.3%$22.23$23.43$22.00300,800
$22.41-0.70-3.0%$23.15$23.27$21.83200,900
$23.11+0.57+2.5%$22.67$23.32$21.71312,600
$22.54-0.13-0.6%$22.73$23.07$22.14253,400
$22.67-0.62-2.7%$23.25$23.65$22.41343,500
$23.29-0.05-0.2%$23.66$23.66$22.60251,600
$23.34-0.17-0.7%$23.85$24.54$22.541,050,100
$23.51-0.16-0.7%$23.54$23.99$23.13234,800
$23.67-0.45-1.9%$24.19$24.66$23.5597,000
$24.12-0.86-3.4%$24.85$24.86$23.06214,400
$24.98-1.52-5.7%$26.56$26.58$24.20207,400
$26.50-0.13-0.5%$26.83$27.58$26.21188,600
$26.63-0.37-1.4%$27.35$27.35$26.31131,800
$27.00-0.21-0.8%$27.30$27.59$26.38330,600
$27.21-0.70-2.5%$28.15$28.71$27.11186,800
$27.91-0.60-2.1%$28.50$29.23$27.68188,400
$28.51-1.20-4.0%$29.71$30.02$27.95220,900
$29.71+0.66+2.3%$29.39$30.73$29.38145,000
$29.05+0.44+1.5%$29.03$29.40$28.56155,000
$28.61-1.87-6.1%$30.06$30.32$28.40252,400
$30.48+0.08+0.3%$30.18$31.00$29.81133,400
$30.40-0.35-1.1%$30.32$31.41$29.96116,600
$30.75+0.83+2.8%$29.85$31.12$29.74159,300
$29.92-0.46-1.5%$30.68$32.52$29.45140,400
$30.38-0.84-2.7%$31.22$31.80$29.77167,300
$31.22+1.28+4.3%$30.00$31.97$28.96240,700
$29.94-5.68-15.9%$35.67$35.67$29.78719,000
$35.62-1.08-2.9%$36.11$36.96$34.95157,800
$36.70+0.73+2.0%$35.76$38.00$35.55278,100
$35.97-1.74-4.6%$37.41$38.85$35.76145,200
$37.71+1.24+3.4%$36.52$38.12$36.52144,458
$36.47-1.16-3.1%$37.28$38.25$35.50222,280
$37.63+1.58+4.4%$36.42$38.23$36.38188,600
$36.05-0.99-2.7%$36.51$37.23$35.68196,800

Splits

1 split · NASDAQ:TECX · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
Ticker
NASDAQ:TECX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Tectonic Therapeutic, Inc. news

Tectonic Therapeutic, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 67 in all · newest Nov 9, 2026 · oldest 2021
Decks
13 decks · latest Aug 6, 2026

Where Tectonic Therapeutic, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TECX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TECXBOATSUnited StatesUSD

Valuation

Price/book 1.8× against a median of 3.4×: 3rd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$178.9M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.95

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tectonic Therapeutic, Inc. · NASDAQ:TECXUS$413.5MUS$178.9Mn/an/an/a1.8×n/a0.0×0.95
Indaptus Therapeutics, Inc. · NASDAQ:INDPUS$433.2MUS$402.6Mn/an/an/a41.9×n/a0.0×1.77
LongBio Pharma (Suzhou) Co., Ltd. Class H · HKEX:1779US$430.7MUS$402.1Mn/an/an/a20.5×n/a0.0×n/a
Ovid Therapeutics Inc. · NASDAQ:OVIDUS$429.7MUS$305.4Mn/a210×n/a2.2×n/a0.1×1.37
Arvinas, Inc. · NASDAQ:ARVNUS$423.0M−US$135.0Mn/a−0.5×n/a0.8×−3.5%0.0×1.25
Prothena Corporation plc · NASDAQ:PRTAUS$422.1MUS$157.0Mn/a3.0×n/a1.6×−45.4%0.0×0.96
TaiMed Biologics Inc. · TPEX:4147US$421.4MUS$385.5Mn/a20.5×n/a3.8×−22.4%0.1×n/a
CHO Pharma, Inc. · TPEX:6586US$413.6MUS$354.2Mn/a8,157×n/a5.7×n/a0.0×n/a
Jacobio Pharmaceuticals Group Co., Ltd. · HKEX:1167US$401.1MUS$173.5Mn/a22.2×n/a2.0×−272.7%0.1×n/a
Candel Therapeutics, Inc. · NASDAQ:CADLUS$395.4MUS$193.8Mn/an/an/a3.0×n/a0.0×2.03
Ever Supreme Bio Technology Co., Ltd. · TPEX:6712US$394.8MUS$362.8M27.5×11.1×23.9×4.6×43.8%0.0×n/a
Median of the othersUS$421.7MUS$329.8M27.5×20.5×23.9×3.4×−22.4%0.0×1.37

Forecasts

8 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
71.00 USD · Analysts' mean
EPS, year to Dec 2026
-5.77 · 1 analyst

Team and board

Officers

OfficerRole
Alise ReicinPresident and CEO, Director
Daniel LochnerChief Financial Officer
Geraldine Peters-WilesSenior Vice President, Human Resources
Mary WestSenior Vice President, Clinical Development Operations
Washington AlvesSenior Vice President, Technical Operations
Marc SchwabishChief Business Officer
Marcella K RuddyChief Medical Officer
Peter McNamaraChief Scientific Officer
Timothy A. SpringerCo-Founder

Board

DirectorRole
François NaderChair, Board of Directors
Alise ReicinPresident and CEO, Director
Jessica ChutterDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+6.3%
Q2 2026Aug 6, 2026 · After close+2.5%
Q1 2026May 7, 2026 · After close+7.9%
Q4 2025Feb 26, 2026+1.5%
Q3 2025Nov 6, 2025 · After close+1.7%
Q2 2025Aug 7, 2025 · After close+1.8%
Q1 2025May 8, 2025 · After close−6.0%
Q4 2024Mar 12, 2025 · After close−4.5%
Q3 2024Nov 7, 2024 · After close−3.0%
Q2 2024Aug 14, 2024 · After close+5.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024−2.4%
Q4 2023Mar 20, 2024−0.8%
Q3 2023Nov 9, 2023−9.9%
Q2 2023Aug 10, 2023+0.7%
Q1 2023May 11, 2023−5.3%
Q4 2022Mar 23, 2023−20.7%
Q3 2022Nov 8, 2022−1.4%
Q2 2022Aug 9, 2022+5.0%
Q1 2022May 10, 2022−7.5%
Q4 2021Mar 17, 2022+11.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck56 slidesAug 6, 2026
Technical Presentation (February 2026)Technical47 slidesFeb 24, 2026
Technical Presentation (October 2025)Technical13 slidesOctober 2025
Investor Presentation (August 2025)Investor deck52 slidesAug 7, 2025
Technical Presentation (May 2025)Technical14 slidesMay 17, 2025
Investor Presentation (January 2025)Investor deck39 slidesJan 13, 2025
Technical Presentation (January 2025)Technical23 slidesJanuary 2025
Technical Presentation (December 2024)Technical36 slidesDec 12, 2024
Investor Presentation (September 2024)Investor deck56 slidesSep 19, 2024
Investor Presentation (July 2024)Investor deck56 slidesJul 30, 2024
All 13 decks
DeckKindSlidesDate
AVROBIO — Merger or Acquisition (April 2024)Merger or acquisition33 slidesApr 4, 2024
Merger or Acquisition (April 2024)Merger or acquisition33 slidesApril 2024
Merger or Acquisition (January 2024)Merger or acquisition33 slidesJanuary 2024

Open Decks

Financings

RaiseDate
Private placement of shares of common stock
Announced: about US$185M · US$50 a share · TD Cowen +3
Dealers: TD Cowen, Leerink Partners, Piper Sandler, Wells Fargo Securities
Buyers: Adage Capital Partners LP; Ally Bridge Group; Deep Track Capital; EcoR1 Capital; Farallon Capital Management, L.L.C. (funds managed by Farallon Capital Management, L.L.C.); Soleus Capital; StemPoint Capital LP; TAS Partners; Woodline Partners LP
Insiders: Individual investors that are officers or directors of Tectonic pay $54.14 per share
Use of proceeds: Clinical development of TX45 and TX2100, discovery platform development, working capital and general corporate purposes
Feb 3, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as AvroBio, Inc. Priced at US$19.00 a share on Jun 20, 2018.

Price
US$19.00 a share
Shares offered
5,247,958 shares of common stock
Offering size
US$99.7 million
Underwriters' option
Up to 787,193 more shares
Underwriters
MORGAN STANLEY, COWEN, WELLS FARGO SECURITIES, WEDBUSH PACGROW · In the order on the cover
Shares delivered
On or about Jun 25, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceApr 6, 2018
Filed publiclyMay 25, 2018
Amended 3 timesNewest Jun 18, 2018
Shares registered with an exchangeJun 18, 2018
Declared effective by the SECJun 20, 2018
Final prospectus, with the priceJun 21, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000
Cost of revenue1.65M617.0K4.17M1.40M1.21M850.0K380.0K45.0K
Gross profit-1.65M-617.0K-4.17M-1.40M-1.21M-850.0K-380.0K-45.0K
Research and development63.5M41.4M37.0M72.2M83.1M87.2M55.0M35.1M15.2M2.66M
Selling, general and administrative20.5M16.7M7.68M7.18M4.63M
Operating income-84.0M-58.0M-44.6M-105.4M-118.8M-120.2M-75.8M-46.2M-18.4M-4.63M
Depreciation and amortization1.38M1.65M1.48M1.44M1.40M1.21M850.0K380.0K45.0K
EBITDA-82.7M-56.4M-43.2M-104.0M-117.4M-119.0M-75.0M-45.9M-18.3M
Interest expense63.0K107.0K152.0K1.81M203.0K
Income before tax-72.9M-58.0M-42.8M-32.2M-8.93M-119.7M-73.0M-46.4M-18.6M-4.66M
Income tax1.23M000
Net income-74.2M-58.0M-42.8M-105.9M-119.1M-119.7M-73.0M-46.4M-18.6M-4.66M
Earnings per share, basic-4.05-6.83-33.76-2.42-2.78-3.31-2.66-3.62-8.38-2.34
Earnings per share, diluted-4.05-6.83-33.76-2.42-2.78-3.31-2.66-3.62-8.38

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents253.8M141.2M28.8M92.6M189.6M259.7M187.0M126.3M5.96M5.36M
Receivables269.0K2.70M2.56M2.14M1.54M
Current assets257.4M146.9M30.9M100.0M199.1M267.2M195.7M130.0M6.31M5.38M
Property, plant and equipment1.19M2.15M3.12M2.89M4.13M3.06M3.70M2.63M349.0K
Total assets261.0M152.9M39.4M103.9M203.8M271.2M200.5M133.5M7.02M5.40M
Accounts payable1.09M976.0K409.0K384.0K3.49M2.68M3.95M2.78M527.0K340.0K
Current liabilities9.67M11.6M40.9M13.1M19.4M16.6M14.0M10.6M2.63M891.0K
Total debt1.28M3.30M4.34M15.0M15.0M
Total liabilities9.71M12.1M43.4M28.6M34.4M16.9M14.5M11.3M3.66M979.0K
Shareholders' equity251.3M140.8M-84.6M-45.7M169.5M254.3M186.0M122.2M-23.1M4.42M
Shares outstanding18.7M14.9M1.41M43.9M43.7M43.7M31.6M23.8M2.31M1.99M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-60.1M-59.1M-40.7M-97.2M-98.0M-98.8M-67.7M-37.6M-16.4M-3.31M
Capital spending-208.0K-156.0K-279.0K-267.0K-2.46M-1.18M-1.58M-1.83M-383.0K0
Free cash flow-60.3M-59.2M-41.0M-97.5M-100.5M-100.0M-69.3M-39.5M-16.8M-3.31M
Cash from investing-138.0K-156.0K-279.0K-267.0K-2.46M-1.18M-1.58M-1.83M-383.0K-24.0K
Cash from financing173.4M171.7M33.7M262.0K30.4M172.6M130.0M160.3M17.4M8.70M
Change in cash113.0M112.5M-7.20M-97.2M-70.1M72.6M60.7M120.8M606.0K5.36M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026Acquisition or disposalSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2026Big-stake noticeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 29, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
144 · Notice of proposed saleAug 27, 2026Other filingsSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Meeting outcomeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 10, 2026Insider tradeSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
8-K · Current reportApr 23, 2026Management or board changeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
S-8 POSMar 9, 2026Offer documentSEC
144 · Notice of proposed saleMar 6, 2026Other filingsSEC
144 · Notice of proposed saleMar 6, 2026Other filingsSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 27, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeFeb 27, 2026Big-stake noticeSEC
8-K · Current reportFeb 26, 2026ResultsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026Management or board changeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2026Big-stake noticeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 29, 2025Current reportSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
8-K · Current reportAug 7, 2025ResultsSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJul 16, 2025Other filingsSEC
424B3 · ProspectusJul 15, 2025Offer documentSEC
CORRESP · Letter to the SECJul 11, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 10, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 9, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 9, 2025Other filingsSEC
POS AM · Amendment to an effective registrationJul 7, 2025Offer documentSEC
POS AM · Amendment to an effective registrationJul 7, 2025Offer documentSEC
S-3 · Registration statementJul 7, 2025Offer documentSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
424B5 · ProspectusJun 11, 2025Offer documentSEC
424B5 · ProspectusJun 11, 2025Offer documentSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
424B5 · ProspectusMay 19, 2025Offer documentSEC
424B5 · ProspectusMay 19, 2025Offer documentSEC
8-K · Current reportMay 19, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
424B3 · ProspectusMay 8, 2025Offer documentSEC
424B3 · ProspectusMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 9, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 7, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 7, 2025Big-stake noticeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 7, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 4, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 3, 2025Other filingsSEC
CORRESP · Letter to the SECMar 31, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 31, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 27, 2025Offer documentSEC
S-1 · Registration statementMar 26, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
DFeb 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
424B5 · ProspectusFeb 12, 2025Offer documentSEC
424B5 · ProspectusFeb 12, 2025Offer documentSEC
424B3 · ProspectusFeb 12, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
8-K · Current reportFeb 3, 2025Material contractSEC
8-K · Current reportJan 30, 2025Current reportSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2025Big-stake noticeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 5, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedOct 28, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 24, 2024Big-stake noticeSEC
4 · Change in ownershipOct 24, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedSep 26, 2024Big-stake noticeSEC
4 · Change in ownershipSep 26, 2024Insider tradeSEC
8-K · Current reportSep 19, 2024Current reportSEC
S-8 POSAug 27, 2024Offer documentSEC
S-8 · Registration statement for employee plansAug 21, 2024Offer documentSEC
8-K · Current reportAug 14, 2024ResultsSEC
424B3 · ProspectusAug 14, 2024Offer documentSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJul 31, 2024Other filingsSEC
424B5 · ProspectusJul 30, 2024Offer documentSEC
8-K · Current reportJul 30, 2024Current reportSEC
424B3 · ProspectusJul 30, 2024Offer documentSEC
CORRESP · Letter to the SECJul 26, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 26, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedJul 22, 2024Big-stake noticeSEC
S-1 · Registration statementJul 19, 2024Offer documentSEC
SC 13G · Big-stake noticeJul 10, 2024Big-stake noticeSEC
8-K · Current reportJul 5, 2024Management or board changeSEC
SC 13G · Big-stake noticeJul 1, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeJun 27, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeJun 26, 2024Big-stake noticeSEC
8-K · Current reportJun 25, 2024Current reportSEC
SC 13D · Big-stake noticeJun 25, 2024Big-stake noticeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC

This page holds 200 of 582 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tectonic Therapeutic, Inc.’s releases · as of Oct 30, 2026

Common shares
19,948,037
Fully diluted
19,948,037

Fully diluted

LineSharesAs of
Common shares19,948,037Oct 30, 2026

Share count over time

CountShares
Oct 30, 202619,948,037

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity2.93M14.7%US$68.3MSep 30, 2026
TCG Crossover Management, LLC1.2M6.0%US$28.1MSep 30, 2026
BlackRock861K4.3%US$20MSep 30, 2026
Vanguard736K3.7%US$17.1MSep 30, 2026
Baker Bros. Advisors LP608K3.0%US$14.2MSep 30, 2026
5AM Venture Management, LLC607K3.0%US$14.1MSep 30, 2026
First Light Asset Management, LLC496K2.5%US$11.6MSep 30, 2026
abrdn485K2.4%US$11.3MSep 30, 2026
Marshall Wace, LLP447K2.2%US$10.4MSep 30, 2026
Braidwell LP371K1.9%US$8.64MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vestal Point Capital, LP360K1.8%US$8.38MSep 30, 2026
Ikarian Capital, LLC306K1.5%US$7.13MSep 30, 2026
Kennedy Capital Management LLC303K1.5%US$7.05MSep 30, 2026
Geode Capital283K1.4%US$6.6MSep 30, 2026
State Street221K1.1%US$5.14MSep 30, 2026
Raymond James Financial Inc197K0.99%US$4.6MSep 30, 2026
Citadel193K0.97%US$4.5MSep 30, 2026
Sphera Funds Management LTD.187K0.94%US$4.37MSep 30, 2026
Goldman Sachs184K0.92%US$4.3MSep 30, 2026
D. E. Shaw & Co., Inc.183K0.92%US$4.25MSep 30, 2026
Qube Research & Technologies Ltd178K0.89%US$4.16MSep 30, 2026
ExodusPoint Capital Management, LP167K0.84%US$3.89MSep 30, 2026
Orbimed Advisors LLC166K0.83%US$3.87MSep 30, 2026
Ameriprise143K0.72%US$3.33MSep 30, 2026
Squarepoint Ops LLC141K0.71%US$3.29MSep 30, 2026
Bollard Group LLC141K0.71%US$3.28MSep 30, 2026
Hrt Financial LP135K0.68%US$3.14MSep 30, 2026
Millennium127K0.64%US$2.96MSep 30, 2026
Hudson Bay Capital Management LP125K0.63%US$2.91MSep 30, 2026
Wells Fargo116K0.58%US$2.69MSep 30, 2026
Northern Trust115K0.58%US$2.68MSep 30, 2026
Woodline Partners LP100K0.50%US$2.33MSep 30, 2026
Balyasny Asset Management L.P.91,0960.46%US$2.12MSep 30, 2026
Boothbay Fund Management, LLC90,2780.45%US$2.1MSep 30, 2026
Morgan Stanley75,1420.38%US$1.75MSep 30, 2026
Sectoral Asset Management Inc72,5920.36%US$1.69MSep 30, 2026
Jane Street67,2470.34%US$1.57MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.64,6870.32%US$1.51MSep 30, 2026
Jump Financial, LLC60,5340.30%US$1.41MSep 30, 2026
Trexquant Investment LP57,8700.29%US$1.35MSep 30, 2026
JPMorgan53,7600.27%US$1.25MSep 30, 2026
Dimensional53,7050.27%US$1.25MSep 30, 2026
ADAR1 Capital Management, LLC49,5010.25%US$1.15MSep 30, 2026
T. Rowe Price48,0010.24%US$1.12MSep 30, 2026
Susquehanna43,6170.22%US$1.02MSep 30, 2026
XTX Topco Ltd41,9630.21%US$977KSep 30, 2026
Y-Intercept (Hong Kong) Ltd41,4630.21%US$966KSep 30, 2026
Wellington37,1490.19%US$865KSep 30, 2026
Aldebaran Capital, LLC36,2200.18%US$844KSep 30, 2026
Schwab31,7650.16%US$740KSep 30, 2026

This page holds 50 of 112 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund720K3.6%US$22.4MMay 31, 2026
Select Biotechnology Portfolio405K2.0%US$12.6MMay 31, 2026
Vanguard Total Stock Market Index Fund364K1.8%US$12.5MJun 30, 2026
iShares Russell 2000 ETF269K1.3%US$9.25MJun 30, 2026
Fidelity Growth Company K6 Fund249K1.2%US$7.75MMay 31, 2026
Fidelity Series Growth Company Fund197K0.99%US$6.12MMay 31, 2026
Columbia Small Cap Growth Fund121K0.61%US$3.79MMay 31, 2026
Fidelity Advisor Biotechnology Fund121K0.61%US$3.39MJul 31, 2026
Fidelity Small Cap Index Fund112K0.56%US$3.14MJul 31, 2026
Vanguard Extended Market Index Fund112K0.56%US$3.85MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Russell 2000 Value ETF78,0650.39%US$2.68MJun 30, 2026
iShares Biotechnology ETF66,5530.33%US$2.29MJun 30, 2026
Vanguard Russell 2000 Index Fund56,3100.28%US$1.75MMay 31, 2026
Fidelity Extended Market Index Fund50,7530.25%US$1.58MMay 31, 2026
iShares Micro-Cap ETF34,4170.17%US$1.18MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.30,6320.15%US$1.05MJun 30, 2026
Small Cap Value Fund28,4080.14%US$977KJun 30, 2026
Schwab Small-Cap Index Fund25,6250.13%US$718KJul 31, 2026
Fidelity Total Market Index Fund19,8260.10%US$618KMay 31, 2026
iShares Russell 2000 Growth ETF19,5390.10%US$672KJun 30, 2026
ALPS Medical Breakthroughs ETF19,3530.10%US$603KMay 31, 2026
Master Small Cap Index Series19,0340.10%US$654KJun 30, 2026
Avantis U.S. Small Cap Equity ETF16,7130.08%US$521KMay 31, 2026
Fidelity Series Total Market Index Fund14,8010.07%US$461KMay 31, 2026
JPMorgan U.S. Small Company Fund13,9710.07%US$480KJun 30, 2026
Nuveen Small Cap Blend Index Fund13,5140.07%US$379KJul 31, 2026
Fidelity Nasdaq Composite Index Fund12,6440.06%US$394KMay 31, 2026
Fidelity Small Cap Value Index Fund11,8020.06%US$406KJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund10,9710.05%US$308KJul 31, 2026
EQ/2000 Managed Volatility Portfolio10,6090.05%US$365KJun 30, 2026
Virtus Biotech Clinical Trials Etf10,2650.05%US$288KJul 31, 2026
JPMorgan Small Cap Value Fund8,8060.04%US$303KJun 30, 2026
Columbia Variable Portfolio - Small Company Growth Fund8,3020.04%US$285KJun 30, 2026
Dimensional U.S. Small Cap ETF7,9960.04%US$224KJul 31, 2026
LVIP State Street Small-Cap Index Fund7,8000.04%US$268KJun 30, 2026
North Square Kennedy Microcap Fund7,3160.04%US$228KMay 31, 2026
Vanguard Russell 2000 Value Index Fund6,9930.04%US$218KMay 31, 2026
AlphaCentric Life Sciences and Healthcare Fund6,9480.03%US$239KJun 30, 2026
Vanguard Balanced Index Fund6,4940.03%US$223KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund5,9790.03%US$206KJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund5,5290.03%US$155KJul 31, 2026
Small Cap Index Fund5,4700.03%US$188KJun 30, 2026
Fidelity ZERO Total Market Index Fund5,3300.03%US$149KJul 31, 2026
iShares Russell 3000 ETF5,3180.03%US$183KJun 30, 2026
Global X Russell 2000 ETF4,8820.02%US$137KJul 31, 2026
Schwab Total Stock Market Index Fund4,7110.02%US$132KJul 31, 2026
Small Cap Index Fund4,4160.02%US$138KMay 31, 2026
Bridge Builder Small/Mid Cap Value Fund4,3230.02%US$149KJun 30, 2026
MetLife Russell 2000 Index Portfolio4,0590.02%US$140KJun 30, 2026
U.S. Small Cap Equity Fund3,9670.02%US$111KJul 31, 2026

This page holds 50 of 130 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
McNamara Peter
Officer: Chief Scientific Officer
Sale536USD 23.04US$12,349Sep 30, 2026
McNamara Peter
Officer: Chief Scientific Officer
Sale43USD 36.52US$1,570Aug 25, 2026
McNamara Peter
Officer: Chief Scientific Officer
Sale43USD 35.00US$1,505Aug 12, 2026
McNamara Peter
Officer: Chief Scientific Officer
Sale172USD 35.00US$6,020Jun 30, 2026
Ruddy Marcella K.
Officer: Chief Medical Officer
Sale1,065USD 30.00US$31,950May 4, 2026
Ruddy Marcella K.
Officer: Chief Medical Officer
Sale1,000USD 31.05US$31,050Apr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Timothy A. Springer31.50%4.31MApr 3, 2025Schedule 13D
FMR LLC15.00%2.8MMar 31, 2025Schedule 13G
Terrance McGuire6.30%658KApr 3, 2025Schedule 13D
Chen Yu6.20%1.17MFeb 12, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ian T. Clark
Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); BioMarin Pharmaceutical Inc. (Chair of the Board, · Since at least Aug 1, 2025); GoodRx Holdings, Inc. (Director · Since at least Jul 8, 2024); Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 7, 2024); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); Guardant Health, Inc. (Director · Since at least Oct 3, 2018); Corvus Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2017); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Kite Pharma Inc (Director · Jan 3, 2017 – Oct 3, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Dec 30, 2016 – May 20, 2022 · Past); Terravia Holdings Inc (Director · May 26, 2011 – May 22, 2017 · Past); Dendreon Corp (Director · Oct 7, 2009 – Aug 20, 2010 · Past); Genentech Inc (EVP-COMMERCIAL · Sep 20, 2006 – Mar 26, 2009 · Past)
Director · Jun 20, 2018 – Jun 6, 2023 · Past
Terrance McGuire
Other companies: Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Since at least Jun 20, 2024
François Nader
Other companies: Moderna, Inc. (Director · Since at least Dec 10, 2019); Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Alexion Pharmaceuticals Inc (Director · Nov 15, 2017 – Jul 21, 2021 · Past); Baxalta Inc (Director · Jul 27, 2015 – Jun 3, 2016 · Past); Acceleron Pharma Inc (Director · Dec 11, 2014 – Nov 19, 2021 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 20, 2015 · Past); NPS Pharmaceuticals Inc (President, CEO and Director, Director · Apr 8, 2013 – Feb 21, 2015 · Past)
Chair, Board of Directors · Since at least Feb 23, 2026
Annalisa Jenkins
Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Serina Therapeutics, Inc. (Director · Nov 27, 2018 – Jun 21, 2021 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past); Ardelyx, Inc. (Director · Apr 20, 2015 – Jun 13, 2019 · Past)
Director · Jun 20, 2018 – Jun 6, 2023 · Past
Phillip Donenberg
Other companies: Sensei Biotherapeutics, Inc. (Chair of the Audit Committee · Since at least Feb 13, 2026); Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Depomed Inc (SVP and CFO · Jul 16, 2018 – Jul 16, 2018 · Past); AveXis Inc (Chief Financial Officer · Oct 19, 2017 – May 15, 2018 · Past); CervoMed Inc. (Director · May 27, 2014 – Jul 24, 2014 · Past); ANI Pharmaceuticals, Inc. (Sr VP of Finance, CFO, Secy · Mar 16, 2006 – Jan 25, 2012 · Past)
Director · Since at least Jun 20, 2018
Alise Reicin
Other companies: Immatics N.V. (Director · Since at least Mar 18, 2026); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Q32 Bio Inc. (Director · Jul 11, 2019 – Jun 14, 2023 · Past); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past)
President and CEO, Director · Since at least Jun 20, 2024
Bruce Booth
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Dianthus Therapeutics, Inc. (Director · Jun 1, 2021 – Jun 28, 2022 · Past)
Director · Jun 10, 2021 – Jun 6, 2023 · Past
Praveen Tipirneni
Other companies: BridgeBio Oncology Therapeutics, Inc. (Non-Executive Director · Since at least Aug 11, 2025); Panacea Acquisition II Corp (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Morphic Holding Inc (President and CEO, Director · Jun 26, 2019 – Aug 16, 2024 · Past)
Director · Since at least Jun 20, 2024
Scott Requadt
Other companies: ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Tourmaline Bio Inc. (Chief Executive Officer, Director · May 6, 2021 – Feb 1, 2023 · Past); VBI Vaccines Inc. (Director · Dec 31, 2016 – Jan 31, 2019 · Past)
Director · Jun 20, 2018 – Jun 25, 2018 · Past
Deanna M Petersen
Other companies: Tecogen Inc. (Director · Dec 31, 2017 – Jul 9, 2020 · Past); American DG Energy Inc (Director · Dec 1, 2014 – May 23, 2017 · Past)
Chief Business Officer · Mar 4, 2020 – Feb 8, 2023 · Past
All 24 people
PersonSeat
Gail M Farfel
Other companies: Durect Corporation (Director · Since at least May 9, 2022); ProMIS Neurosciences Inc. (Chief Executive Officer, Director · Sep 19, 2022 – Aug 23, 2023 · Past)
Director · Jun 8, 2022 – Jun 6, 2023 · Past
Marcella Kuhlman Ruddy
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Upstream Bio, Inc. (Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024)
Chief Medical Officer · Since at least Jun 20, 2024
Stefan Vitorovic
Other companies: Vigil Neuroscience Inc (Director · Since at least Jun 9, 2022); Praxis Precision Medicines, Inc. (Director · May 26, 2022 – May 26, 2022 · Past)
Director · Since at least Jun 20, 2024
Birgitte Volck
Other companies: Soleno Therapeutics, Inc. (Director · Since at least Jun 10, 2019)
President of R&D · Dec 17, 2018 – Mar 4, 2020 · Past
Christian Cortis
Other companies: Agenus Inc. (Chief Strategy Officer · Jun 19, 2019 – Jul 23, 2019 · Past)
Chief Operating Officer · Jun 20, 2024 – Jun 20, 2024 · Past
Daniel Lochner
Other companies: Oyster Point Pharma Inc (Chief Financial Officer · Oct 30, 2019 – Dec 1, 2022 · Past)
Chief Financial Officer · Since at least Jun 20, 2024
Erik Ostrowski
Other companies: Akebia Therapeutics, Inc. (Senior Vice President, Chief Financial Officer and Chief Business Officer · Since at least Jun 24, 2024)
Interim CEO, President and CFO · Jan 2, 2019 – Feb 1, 2024 · Past
Geoffrey Mackay
Other companies: Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past)
President & CEO, Director · Jun 20, 2018 – Feb 8, 2023 · Past
Azadeh GolipourChief Technology Officer · Feb 1, 2024 – Feb 1, 2024 · Past
Christopher PaigeDirector · Jun 20, 2018 – Jun 6, 2023 · Past
Essra RidhaChief Medical Officer · Oct 19, 2021 – Feb 1, 2024 · Past
Jessica ChutterDirector · Since at least Apr 23, 2026
Marc SchwabishChief Business Officer · Since at least Jun 20, 2024
Peter McNamaraChief Scientific Officer · Since at least Jun 30, 2026

Open People

Log in to ask 6ix AI your own questions about Tectonic Therapeutic, Inc.